Who is sponsoring NCT03108768?

NCT03108768 is sponsored by Sonova AG.

What drugs are being tested in NCT03108768?

Interventions in NCT03108768: Hearing Aid (Successor of Phonak Virto V), Hearing Aid (Phonak Virto V).

What condition does NCT03108768 study?

NCT03108768 studies Hearing Loss, Bilateral Sensorineural, Progressive.

Is NCT03108768 still recruiting?

NCT03108768 is currently completed. Last updated 16 June 2017.

Last reviewed 2017-06-16 · How we verify

NCT03108768

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Quality Control of CE-Certified Phonak Hearing Aids - 2016_37

Completed NA Last updated 16 June 2017

What this trial tests

NA trial testing Hearing Aid (Successor of Phonak Virto V) in Hearing Loss, Bilateral Sensorineural, Progressive in 20 participants. Completed in 14 June 2017.

Timeline

3 April 2017

Primary endpoint
14 June 2017

14 June 2017

Quick facts

Lead sponsor	Sonova AG
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	20
Start date	3 April 2017
Primary completion	14 June 2017
Estimated completion	14 June 2017
Sites	1 location across Switzerland

Drugs / interventions tested

Hearing Aid (Successor of Phonak Virto V)
Hearing Aid (Phonak Virto V)

Conditions studied

Hearing Loss, Bilateral Sensorineural, Progressive — all drugs for Hearing Loss, Bilateral Sensorineural, Progressive →

Sponsor

Sonova AG — full company profile →

Who can join

Adults 18 to 99, any sex, with Hearing Loss, Bilateral Sensorineural, Progressive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A methodical evaluation of new CE-labelled Phonak Hearing Systems is intended to be conducted on hard of participants with a hearing loss to grant quality control prior to product launch. The aim of the investigation series is to ensure zero-defect overall performance of the new hearing systems as well as maximum benefit for the participant with the devices in comparison to previously outstanding Phonak Hearing Systems.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Sonova AG trials

Trials by the same sponsor.

NCT07526428 — Investigating the DNN Noise Reduction Feature in Phonak Hearing Aids Using Ecological Momentary Assessment · NA · enrolling by invitation
NCT07501312 — Remote Microphone Performance Comparison in Adults With Hearing Loss · NA · enrolling by invitation
NCT07414329 — Efficacy and Effectiveness of an Investigational Behind-the-Ear Hearing Device Kit · NA · recruiting
NCT06957730 — A Comparison of Hearing Aid Noise Programs on Speech Intelligibility · NA · completed
NCT06746038 — Evaluation of Extended Wear Hearing Aid for Mild Hearing Loss · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03108768 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sonova AG
Last refreshed: 16 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03108768.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing